Please wait
0001585364333-282001S-3424B5EX-FILING FEESfalsefalsetruetrue11 0001585364 2024-09-13 2024-09-13 0001585364 1 2024-09-13 2024-09-13 0001585364 3 2024-09-13 2024-09-13 0001585364 2 2024-09-13 2024-09-13 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107.1
Calculation of Filing Fee Table
424(b)(5)
(Form Type)
Issuer:
Perrigo Company plc
Perrigo Finance Unlimited Company
Guarantors:
Athena Neurosciences, LLC
Chefaro Ireland Designated Activity Company
Elan Pharmaceuticals, LLC
Galpharm Healthcare Limited
Galpharm International Limited
Gr8ness, LLC
L. Perrigo Company
Medgenix Benelux NV
OCE-BIO
BV
Perrigo Belgium NV
Perrigo Capital NV
Omega Pharma Innovation & Development NV
Omega Pharma International NV
Omega Pharma Limited
Omega Pharma Trading NV
Omega Teknika Designated Activity Company
PBM Canada Holdings, LLC
PBM Nutritionals, LLC
PBM Products, LLC
Perrigo Americas Holdings, Inc.
Perrigo Company
Perrigo Corporation Designated Activity Company
Perrigo Diabetes Care, LLC
Perrigo Direct, Inc.
Perrigo Europe Invest NV
Perrigo Finance (US) LLC
Perrigo Florida, Inc.
Perrigo Holding NV
Perrigo Holdings Unlimited Company
Perrigo International Finance Designated Activity Company
Perrigo International Holdings II, Inc.
Perrigo International Holdings, LLC

Perrigo International, Inc.
Perrigo Investments, LLC
Perrigo Ireland 1 Designated Activity Company
Perrigo Ireland 10 Unlimited Company
Perrigo Supply Chain International Designated Activity Company
Perrigo Ireland 13 Designated Activity Company
Perrigo Ireland 2 Designated Activity Company
Perrigo Ireland 4 Unlimited Company
Perrigo Ireland 5 Unlimited Company
Perrigo Ireland 6 Unlimited Company
Perrigo Ireland 9 Unlimited Company
Perrigo Management Company
Perrigo Mexico Investment Holdings, LLC
Perrigo New York, Inc.
Perrigo Pharma International Designated Activity Company
Perrigo Pharma Limited
Perrigo Research & Development Company
Perrigo Sales Corporation
Perrigo UK Acquisition Limited
PMI Branded Pharmaceuticals, Inc.
Ranir Global Holdings, LLC
Ranir (Holdings) Limited
Ranir, LLC
Wrafton Laboratories Limited
(Exact Name of Registrant as Specified in its Charter)

 
Table 1: Newly Registered and Carry Forward Securities
 
                         
    
Security 
Type 
 
Security
Class
Title
 
Fee
Calculation
or Carry
Forward
Rule
 
Amount
Registered
 
Proposed
Maximum
Offering
Price Per
Unit
 
Maximum
Aggregate
Offering
Price
 
Fee
Rate
 
Amount of
Registration
Fee
(2)
 
Carry
Forward
Form
Type
 
Carry
Forward
File
Number
 
Carry
Forward
Initial
effective
date
 
Filing Fee
Previously
Paid in
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
                         
Fees to
Be Paid
  Debt   6.125% Notes due 2032  
Rule 
457(r)
(1) 
  $715,000,000  
100
% 
  $715,000,000   0.00014760   $105,534                      
                         
    Debt   5.375% Notes due 2032  
Rule 
457(r)
(1) 
  $387,940,000
(1)
 
100
% 
  $387,940,000   0.00014760   $57,260          
                         
Fees Previously Paid
  —      —                     
 
Carry Forward Securities
                         
Carry Forward Securities
  —    —    —    —    —    —             
                         
     
Total Offering
Amounts
        $1,102,940,000     $162,794          
                         
     
Total Fees Previously
Paid
            $0          
                         
     
Total Fee Offsets
            $0          
                         
       
Net Fee Due
                      $162,794                
 
(1)
The U.S. dollar equivalent of the amount registered has been calculated using the exchange rate for September 6, 2024 of U.S. $1.1084=EUR 1, as published by Bloomberg L.P.
(2)
The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings. The maximum aggregate offering price of those offerings is $1,102,940,000.